RESUMEN
@#Tuberculosis(TB)treatment is currently falling into a gigantic dilemma-particularly with the increased frequentcy TB resistance, so the development of new anti-tuberculosis drugs is imperative and has received extensive attention. In the past decade, significant progress has been made in this field. Bedaquiline, delamanid and pretomanid have been approved for the clinical use. In addition, many other drugs and combination protocols are undergoing clinical trials. This review focuses on the new chemical entities for TB treatments from multiple perspectives, including the mechanisms of action, in vitro and in vivo pharmacological activities, pharmacokinetic properties and clinical results. Anti-tuberculosis drug research is prospected to provide a reference for drug deve-lopment.